SCHEDULE: Frazier Funds Disclose Lexeo Therapeutics Stake
Schedule 13G Amendment
Frazier Life Sciences Public Fund and affiliated entities filed an amended Schedule 13G, disclosing beneficial ownership in Lexeo Therapeutics, Inc. as of December 31, 2025.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) and its general partners beneficially own 3,698,271 shares of Lexeo Therapeutics, Inc. Common Stock, representing 5.1% of the class.
- This ownership includes shares acquired from Frazier Life Sciences Public Overage Fund, L.P. through a merger.
- Additional affiliated entities, Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., and Frazier Life Sciences XII, L.P., along with their respective general partners and managing members James N. Topper and Patrick J. Heron, also reported beneficial ownership of Lexeo Therapeutics shares.
- Frazier Life Sciences X, L.P. beneficially owns 87,424 shares (0.1%).
- Frazier Life Sciences XI, L.P. beneficially owns 232,784 shares (0.3%).
- Frazier Life Sciences XII, L.P. beneficially owns 406,246 shares (0.6%).
- The reported beneficial ownership percentages are calculated based on 72,987,327 shares of Common Stock outstanding as of November 3, 2025.
- The reported amounts do not include certain warrants and prefunded warrants to acquire additional shares, which are subject to a 9.99% beneficial ownership limitation upon exercise.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive disclosure, as it confirms significant institutional ownership by Frazier Life Sciences funds, which can be interpreted as a vote of confidence in Lexeo Therapeutics. The filing is purely factual and does not contain negative information.
Positives
- Significant institutional investment by Frazier Life Sciences funds, indicating confidence in Lexeo Therapeutics.
- Frazier Life Sciences Public Fund, L.P. holds a 5.1% stake, exceeding the 5% threshold for Schedule 13G reporting, signifying a notable position.
- The collective ownership across various Frazier funds and individuals demonstrates a broader institutional interest.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can be a positive signal for a biotechnology company like Lexeo Therapeutics, often indicating investor confidence in its pipeline or market position. Frazier Life Sciences is a prominent investor in the life sciences sector.
Stakeholder Impact
- Shareholders: Increased transparency regarding significant institutional ownership. May signal confidence from a reputable life sciences investor.
- Company Management: Awareness of a substantial institutional shareholder base.
Key Dates
| Date | Description |
|---|---|
| 2025-11-03 | Date on which 72,987,327 shares of Common Stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2025-12-31 | Date of event which requires filing of this statement (reporting date for ownership). |
| 2026-01-27 | Date a Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC. |
| 2026-02-13 | Date of signing for the Joint Filing Agreement and the Schedule 13G. |
Recommendation
holdThis Schedule 13G filing primarily serves as a disclosure of beneficial ownership by Frazier Life Sciences funds. While the presence of a significant institutional investor like Frazier can be a positive signal, indicating confidence in Lexeo Therapeutics, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It confirms existing institutional interest, suggesting a 'hold' is appropriate for investors awaiting further fundamental updates.
Keywords
Lexeo Therapeutics, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals, Investment Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.